Clinically, OAS2 was associated with poor patient survival in breast cancer, supporting its potential as a stress-adaptive but pro-tumorigenic factor [15,16] and reinforcing the adverse prognostic implications of COX-2. This evidence concerns the gene OAS2 and breast cancer.